Backed by a treatment-tuning platform, Allay Therapeutics is giving pain relief a major upgrade. Rather than relying on drugs repeatedly administered by capsule or IV to find their way to the point of pain, Allay’s analgesics are implanted directly into the surgical site and, thanks to slow-dissolving biopolymers, can provide post-op relief for several weeks.

Tyra Biosciences is the latest biotech to rake in an upsized IPO. Its $172.8 million deal will push three programs targeting drug-resistant cancers into the clinic.

Though Mesa Laboratories has spent much of its lifetime working behind the scenes, manufacturing software and supplies used to help healthcare providers, medical device makers and life sciences labs run smoothly, the Colorado-based company is ready for its moment in the spotlight.

After seeing Ra Pharmaceuticals, Disarm Therapeutics and Tizona Therapeutics to exits last year, Lightstone Ventures is back with $375 million to plant a seed in early-stage biotech and medtech startups.

Pfizer was in a hurry to seal its takeover of cancer startup Trillium Therapeutics, a relationship that was first sparked after the Big Pharma spied some early clinical data at the American Society of Clinical Oncology (ASCO) annual meeting in June 2020.

As its name suggests, Vanqua Bio wants to vanquish neurodegenerative diseases like Parkinson’s and Alzheimer’s. Now, the biotech has $85 million in series B funds from a series of venture firms and Big Pharma Eli Lilly to start human trials within two years. 

Astellas has seen a fourth death of a young child in its gene therapy trial of an experimental drug gained through the pharma’s $3 billion buyout of biotech Audentes.

Zoll Medical isn’t resting when it comes to building out its sleep apnea portfolio, with a $538 million acquisition of Itamar Medical, the maker of at-home diagnostic products aimed at long-term heart complications.

After penning a major funding round earlier this year, the artificial intelligence-powered drug designer Exscientia is showing no signs of slowing down, with the announcement of plans to go public.

AltruBio has signed a new chief medical officer, five months after a makeover that saw it change its name, its focus and its board.